A Chinese single-dose COVID-19 vaccine shows a 65.7-percent efficacy at preventing symptomatic cases and a 90.98-percent efficacy against severe disease in an interim analysis of its global phase-3 clinical trials, said recent media reports.
The efficacy of the Ad5-nCoV vaccine is based on multi-country analysis of 30,000 participants and 101 virologically confirmed COVID-19 cases conducted by an independent data monitoring committee in Pakistan, Reuters cited a Pakistani health official to report on Monday.
"In the Pakistan subset, efficacy at preventing symptomatic cases is 74.8 percent and 100 percent at preventing severe disease," Faisal Sultan, special assistant to the Pakistani Prime Minister on Health, tweeted Monday, adding that the committee has not reported any serious safety concerns.
CanSino has been conducting phase-3 clinical trails in Russia, Pakistan, and Mexico, and seeking approvals for phase-3 clinical trials in several other countries, the company said in a release in November last year.
The vaccine candidate was co-developed by CanSino and the Academy of Military Sciences in China.
